Additionally, human subjects bearing an SLC6A19 loss-of-function mutation develop a disorder called Hartnup disease, characterized notably by the co-occurrence of neuropsychiatric symptoms and low blood levels of neutral amino acids [62,63]. Here, SLC6A19 is linked to Hartnup disease.